文献速递胸部肿瘤

吗啡与二甲双胍影响非小细胞肺癌患者免疫治疗获益:IFCT-1502 CLINIVO-SNDS真实世界研究结果

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.
PubMed 文献 · Eur J Cancer · 2025-06-11

该研究基于法国扩大可及性项目纳入了753例接受纳武利尤单抗二线及以上治疗的晚期非小细胞肺癌患者,从法国国家医疗数据库中检索首次给药前90天至后30天的合并用药处方。多因素分析显示,吗啡和每日剂量超过20 mg的糖皮质激素与较差的总生存期相关,且不依赖于疾病侵袭性;二甲双胍则与更好的总生存期相关。吗啡和糖皮质激素还与更短的真实世界无进展生存期相关。

要点

  • 吗啡和每日剂量超过20 mg的糖皮质激素与较差的总生存期相关,且不依赖于疾病侵袭性。
  • 二甲双胍与更好的总生存期相关。
  • 吗啡和糖皮质激素还与更短的真实世界无进展生存期相关。

核心结论

  • 研究证实吗啡和高剂量糖皮质激素对免疫治疗疗效有负面影响,且不依赖于与疾病侵袭性相关的预后不良因素。
  • 研究结果提示二甲双胍对免疫治疗结局有正面影响。

研究设计与样本

  • IFCT-1502 CLINIVO研究是一项全国性回顾性队列研究,纳入在法国扩大可及性项目下接受纳武利尤单抗二线或后线治疗的晚期非小细胞肺癌患者。
  • 通过法国国家医疗数据库检索首次纳武利尤单抗给药前90天至后30天的合并用药处方。
  • 报告了一项事后分析结果,在考虑已知负面预后因素的情况下研究合并用药对治疗反应的影响。
  • 共选择753例医疗和合并用药记录可用的患者。

主要发现

  • 多因素分析显示,吗啡和每日剂量超过20 mg的糖皮质激素与较差的总生存期相关,且不依赖于疾病侵袭性。
  • 多因素分析显示,二甲双胍与更好的总生存期相关。
  • 多因素分析显示,吗啡和糖皮质激素与更短的真实世界无进展生存期相关。
  • 肝转移和东部肿瘤协作组(ECOG)体能状态(PS)评分≥2等预后不良因素也与更短的真实世界无进展生存期相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients with lung cancer have comorbidities at the time of diagnosis. Treatments prescribed for cancer-related symptoms are thus added to drugs for chronic diseases. The impact of comedication on immunotherapy efficacy has been studied in retrospective series, but the results are often biased by the lack of information on the independent prognostic impact of comedication weighted for comorbidities and disease aggressiveness. METHODS: The IFCT-1502 CLINIVO study is a nationwide retrospective cohort of patients with advanced non-small cell lung cancer who received nivolumab in second or later lines of treatment as part of the French Expanded Access Program. We retrieved comedication prescriptions from 90 days before to 30 days after the first nivolumab administration via the French national healthcare database. We report the results of a comprehensive post hoc analysis investigating the impact of comedication on treatment response considering well-known negative prognostic factors. RESULTS: We selected 753 patients whose medical and comedication records were available. According to the multivariate analysis, morphine and corticosteroids > 20 mg per day were associated with poor overall survival regardless of disease aggressiveness. Conversely, metformin was associated with better overall survival. Morphine and corticosteroids were also found to be associated with shorter real-world progression-free survival according to multivariate analysis, as were poor prognostic factors such as liver metastasis and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≥ 2. CONCLUSION: Our study confirmed the negative impact of morphine and high-dose corticosteroids on immunotherapy efficacy regardless of poor prognostic factors related to disease aggressiveness. On the other hand, our findings suggested a positive impact of metformin on immunotherapy outcomes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gobbini E, Langlais A, Missy P, et al. Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS. Eur J Cancer. 2025. PMID: 40532471. doi:10.1016/j.ejca.2025.115560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。